Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ASCO Annual Meeting 2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

2024 ASCO Annual Meeting

Keep up to date with all the top stories and latest evidence with our hub page, including official congress videos and expert takeaways.
ADVANCED SEARCH
Log in
Top
BMC Pulmonary Medicine
Published in: BMC Pulmonary Medicine 1/2022

Open Access 01-12-2022 | Chronic Obstructive Lung Disease | Research

Analysis of the association of ANO3/MUC15, COL4A4, RRBP1, and KLK1 polymorphisms with COPD susceptibility in the Kashi population

Authors: Lifeng Tang, Xuemei Zhong, Hui Gong, Maimaitiaili Tuerxun, Tao Ma, Jie Ren, Chengxin Xie, Aifang Zheng, Zulipikaer Abudureheman, Ayiguzali Abudukadeer, Paierda Aini, Subinuer Yilamujiang, Li Li

Published in: BMC Pulmonary Medicine | Issue 1/2022

Login to get access

Abstract

Objective

Chronic obstructive pulmonary disease (COPD) is a complex, multifactorial, polygenic disease. The rate of occurrence of COPD in the Kashi population (Uyghur) is significantly higher than that observed nationwide. The identification of COPD-related genes in the Chinese Uyghur population could provide useful insights that could help us understand this phenomenon. Our previous whole-exome sequencing study of three Uyghur families with COPD demonstrated that 72 mutations in 55 genes might be associated with COPD; these included rs15783G > A in the anoctamin 3 (ANO3) gene/mucin 15 (MUC15) gene, rs1800517G > A in the collagen type IV alpha 4 chain (COL4A4) gene, rs11960G > A in the ribosome binding protein 1 (RRBP1) gene, and rs5516C > G in the kallikrein 1 (KLK1) gene. This case–control study aimed to further validate the association of the four mutations with COPD in the Chinese Uyghur population.

Methods

Sanger sequencing was used for the genotyping of four polymorphisms (ANO3/MUC15 rs15783, COL4A4 rs1800517, RRBP1 rs11960, and KLK1 rs5516) in 541 unrelated Uyghur COPD patients and 534 Uyghur healthy controls. We then conducted stratified analyses based on the smoking status and airflow limitation severity, to explore the correlation between selected gene polymorphisms and COPD.

Results

ANO3/MUC15 rs15783 and KLK1 rs5516 polymorphisms could significantly reduce COPD risk (p < 0.05), but COL4A4 rs1800517 and RRBP1 rs11960 polymorphisms were not correlated with COPD in the entire population. In a stratified analysis of smoking status, non-smokers with the ANO3/MUC15 rs15783G/G genotype (OR = 0.63, p = 0.032) or COL4A4 rs1800517 allele G (OR = 0.80, p = 0.023) had a reduced risk of COPD. Smokers with the RRBP1 rs11960A/G genotype had a lower risk of COPD (OR = 0.41, p = 0.025). The KLK1 rs5516G > C polymorphism was associated with a decreased risk of COPD (OR < 1, p < 0.05), irrespective of the smoking status of individuals. No significant association with COPD severity was observed in individuals with these four polymorphisms (p > 0.05).

Conclusion

We identified four previously unreported mutations (ANO3/MUC15 rs15783, COL4A4 rs1800517, RRBP1 rs11960, and KLK1 rs5516) that might decrease the COPD risk in individuals with different smoking statuses in the Chinese Uyghur population. Our findings provide new light for the genetic risk factors associated with the occurrence of COPD.
Appendix
Available only for authorised users
Literature
1.
Vogelmeier CF, Criner GJ, Martinez FJ, Anzueto A, Barnes PJ, Bourbeau J, Celli BR, Chen R, Decramer M, Fabbri LM, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease 2017 report. GOLD executive summary. Am J Respir Crit Care Med. 2017;195(5):557–82.PubMedCrossRef
2.
Collaborators GBDCoD. Global, regional, and national age-sex specific mortality for 264 causes of death, 1980–2016: a systematic analysis for the global burden of disease study 2016. Lancet. 2017;390(10100):1151–210.CrossRef
3.
4.
Ruvuna L, Sood A. Epidemiology of chronic obstructive pulmonary disease. Clin Chest Med. 2020;41(3):315–27.PubMedCrossRef
5.
Li L, Zhong X, Zheng A, JianKun C, Budukadeer AA, Aini P, Tuerxun M, Yasen M, Ma T, Ren J, et al. Prevalence and risk factors of chronic obstructive pulmonary disease in Kashi region, Northwestern China. Int J Chron Obstr Pulm Dis. 2021;16:655–63.CrossRef
6.
Wang C, Xu J, Yang L, Xu Y, Zhang X, Bai C, Kang J, Ran P, Shen H, Wen F, et al. Prevalence and risk factors of chronic obstructive pulmonary disease in China (the China pulmonary health [CPH] study): a national cross-sectional study. Lancet. 2018;391(10131):1706–17.PubMedCrossRef
7.
Choi M, Scholl UI, Ji W, Liu T, Tikhonova IR, Zumbo P, Nayir A, Bakkaloglu A, Ozen S, Sanjad S, et al. Genetic diagnosis by whole exome capture and massively parallel DNA sequencing. Proc Natl Acad Sci U S A. 2009;106(45):19096–101.PubMedPubMedCentralCrossRef
8.
Xu J, Li L, Ren J, Zhong X, Xie C, Zheng A, Abudukadier A, Tuerxun M, Zhang S, Tang L, et al. Whole-exome sequencing implicates the USP34 rs777591A > G intron variant in chronic obstructive pulmonary disease in a Kashi cohort. Front Cell Dev Biol. 2021;9: 792027.PubMedCrossRef
9.
Busch R, Hobbs BD, Zhou J, Castaldi PJ, McGeachie MJ, Hardin ME, Hawrylkiewicz I, Sliwinski P, Yim JJ, Kim WJ, et al. Genetic association and risk scores in a chronic obstructive pulmonary disease meta-analysis of 16,707 subjects. Am J Respir Cell Mol Biol. 2017;57(1):35–46.PubMedPubMedCentralCrossRef
10.
11.
Gong H, Ren J, Xu J, Zhong X, Abudureheman Z, Yilamujiang S, Xie C, Ma T, Li F, Tang L, et al. SMAD3 rs36221701 T>C polymorphism impacts COPD susceptibility in the Kashi population. Gene. 2022;808: 145970.PubMedCrossRef
12.
Su J, Ye Q, Zhang D, Zhou J, Tao R, Ding Z, Lu G, Liu J, Xu F. Joint association of cigarette smoking and PM2.5 with COPD among urban and rural adults in regional China. BMC Pulm Med. 2021;21(1):87.PubMedPubMedCentralCrossRef
13.
Postma DS, Bush A, van den Berge M. Risk factors and early origins of chronic obstructive pulmonary disease. Lancet. 2015;385(9971):899–909.PubMedCrossRef
14.
Dizier MH, Margaritte-Jeannin P, Madore AM, Esparza-Gordillo J, Moffatt M, Corda E, Monier F, Guilloud-Bataille M, Franke A, Weidinger S, et al. The ANO3/MUC15 locus is associated with eczema in families ascertained through asthma. J Allergy Clin Immunol. 2012;129(6):1547–53.PubMedCrossRef
15.
16.
Le SC, Yang H. Structure-function of TMEM16 ion channels and lipid scramblases. Adv Exp Med Biol. 2021;1349:87–109.PubMedCrossRef
17.
Zhou-Suckow Z, Duerr J, Hagner M, Agrawal R, Mall MA. Airway mucus, inflammation and remodeling: emerging links in the pathogenesis of chronic lung diseases. Cell Tissue Res. 2017;367(3):537–50.PubMedCrossRef
18.
Lange LM, Junker J, Loens S, Baumann H, Olschewski L, Schaake S, Madoev H, Petkovic S, Kuhnke N, Kasten M, et al. Genotype-phenotype relations for isolated dystonia genes: MDSGene systematic review. Mov Disord. 2021;36(5):1086–103.PubMedCrossRef
19.
20.
Pallesen LT, Berglund L, Rasmussen LK, Petersen TE, Rasmussen JT. Isolation and characterization of MUC15, a novel cell membrane-associated mucin. Eur J Biochem. 2002;269(11):2755–63.PubMedCrossRef
21.
Zhang S, Zhang W, Xiao Y, Qin T, Yue Y, Qian W, Shen X, Ma Q, Wang Z. Targeting MUC15 protein in cancer: molecular mechanisms and therapeutic perspectives. Curr Cancer Drug Targets. 2020;20(9):647–53.PubMedCrossRef
22.
Loscertales M, Nicolaou F, Jeanne M, Longoni M, Gould DB, Sun Y, Maalouf FI, Nagy N, Donahoe PK. Type IV collagen drives alveolar epithelial-endothelial association and the morphogenetic movements of septation. BMC Biol. 2016;14:59.PubMedPubMedCentralCrossRef
23.
24.
Harris B, Klein R, Jerosch-Herold M, Hoffman EA, Ahmed FS, Jacobs DR Jr, Klein BE, Wong TY, Lima JA, Cotch MF, et al. The association of systemic microvascular changes with lung function and lung density: a cross-sectional study. PLoS ONE. 2012;7(12): e50224.PubMedPubMedCentralCrossRef
25.
Kyomoto Y, Kanazawa H, Tochino Y, Watanabe T, Asai K, Kawaguchi T. Possible role of airway microvascular permeability on airway obstruction in patients with chronic obstructive pulmonary disease. Respir Med. 2019;146:137–41.PubMedCrossRef
26.
Thomsen MS, Birkelund S, Burkhart A, Stensballe A, Moos T. Synthesis and deposition of basement membrane proteins by primary brain capillary endothelial cells in a murine model of the blood-brain barrier. J Neurochem. 2017;140(5):741–54.PubMedCrossRef
27.
Storey H, Savige J, Sivakumar V, Abbs S, Flinter FA. COL4A3/COL4A4 mutations and features in individuals with autosomal recessive alport syndrome. J Am Soc Nephrol. 2013;24(12):1945–54.PubMedPubMedCentralCrossRef
28.
Guo L, Li D, Dong S, Wan D, Yang B, Huang Y. Mutation analysis of COL4A3 and COL4A4 genes in a Chinese autosomal-dominant Alport syndrome family. J Genet. 2017;96(2):389–92.PubMedCrossRef
29.
Oakes SA, Papa FR. The role of endoplasmic reticulum stress in human pathology. Annu Rev Pathol. 2015;10:173–94.PubMedCrossRef
30.
Read A, Schroder M. The unfolded protein response: an overview. Biology (Basel). 2021;10(5):384.
31.
Savitz AJ, Meyer DI. Identification of a ribosome receptor in the rough endoplasmic reticulum. Nature. 1990;346(6284):540–4.PubMedCrossRef
32.
Tsai HY, Yang YF, Wu AT, Yang CJ, Liu YP, Jan YH, Lee CH, Hsiao YW, Yeh CT, Shen CN, et al. Endoplasmic reticulum ribosome-binding protein 1 (RRBP1) overexpression is frequently found in lung cancer patients and alleviates intracellular stress-induced apoptosis through the enhancement of GRP78. Oncogene. 2013;32(41):4921–31.PubMedCrossRef
33.
Wang W, Wang M, Xiao Y, Wang Y, Ma L, Guo L, Wu X, Lin X, Zhang P. USP35 mitigates endoplasmic reticulum stress-induced apoptosis by stabilizing RRBP1 in non-small cell lung cancer. Mol Oncol. 2021;16(7):1572–90.
34.
Wang HL, Chen FQ, Wu LJ. Ephedrine ameliorates chronic obstructive pulmonary disease (COPD) through restraining endoplasmic reticulum (ER) stress in vitro and in vivo. Int Immunopharmacol. 2022;103: 107842.PubMedCrossRef
35.
Tang F, Ling C. Curcumin ameliorates chronic obstructive pulmonary disease by modulating autophagy and endoplasmic reticulum stress through regulation of SIRT1 in a rat model. J Int Med Res. 2019;47(10):4764–74.PubMedPubMedCentralCrossRef
36.
Wang Y, Wu ZZ, Wang W. Inhibition of endoplasmic reticulum stress alleviates cigarette smoke-induced airway inflammation and emphysema. Oncotarget. 2017;8(44):77685–95.PubMedPubMedCentralCrossRef
37.
Li X, Michaeloudes C, Zhang Y, Wiegman CH, Adcock IM, Lian Q, Mak JCW, Bhavsar PK, Chung KF. Mesenchymal stem cells alleviate oxidative stress-induced mitochondrial dysfunction in the airways. J Allergy Clin Immunol. 2018;141(5):1634–45.
38.
Naiel S, Tat V, Padwal M, Vierhout M, Mekhael O, Yousof T, Ayoub A, Abed S, Dvorkin-Gheva A, Ask K. Protein misfolding and endoplasmic reticulum stress in chronic lung disease: Will cell-specific targeting be the key to the cure? Chest. 2020;157(5):1207–20.PubMedCrossRef
39.
Stockley RA. Neutrophils and protease/antiprotease imbalance. Am J Respir Crit Care Med. 1999;160(5 Pt 2):S49-52.PubMedCrossRef
40.
Casalino-Matsuda SM, Monzon ME, Forteza RM. Epidermal growth factor receptor activation by epidermal growth factor mediates oxidant-induced goblet cell metaplasia in human airway epithelium. Am J Respir Cell Mol Biol. 2006;34(5):581–91.PubMedPubMedCentralCrossRef
41.
Shaykhiev R, Zuo WL, Chao I, Fukui T, Witover B, Brekman A, Crystal RG. EGF shifts human airway basal cell fate toward a smoking-associated airway epithelial phenotype. Proc Natl Acad Sci U S A. 2013;110(29):12102–7.PubMedPubMedCentralCrossRef
42.
Casalino-Matsuda SM, Monzon ME, Conner GE, Salathe M, Forteza RM. Role of hyaluronan and reactive oxygen species in tissue kallikrein-mediated epidermal growth factor receptor activation in human airways. J Biol Chem. 2004;279(20):21606–16.PubMedCrossRef
43.
Forteza R, Casalino-Matsuda SM, Monzon ME, Fries E, Rugg MS, Milner CM, Day AJ. TSG-6 potentiates the antitissue kallikrein activity of inter-alpha-inhibitor through bikunin release. Am J Respir Cell Mol Biol. 2007;36(1):20–31.PubMedCrossRef
44.
Zhang Y, Huang H, Ma Y, Sun Y, Wang G, Tang L. Association of the KLK1 rs5516 G allele and the ACE D allele with aortic aneurysm and atherosclerotic stenosis. Medicine (Baltimore). 2016;95(44): e5120.CrossRef
45.
Zhang Y, Huang H, Ma Y, Sun Y, Wang G, Tang L. Analysis of KLK1 polymorphism (rs5516) in patients with abdominal aortic aneurysm or thoracic aortic dissection. J Cardiovasc Surg (Torino). 2018;59(2):293–6.
46.
Liu K, Li QZ, Delgado-Vega AM, Abelson AK, Sanchez E, Kelly JA, Li L, Liu Y, Zhou J, Yan M, et al. Kallikrein genes are associated with lupus and glomerular basement membrane-specific antibody-induced nephritis in mice and humans. J Clin Invest. 2009;119(4):911–23.PubMedPubMedCentralCrossRef
47.
Jiang S, Hsu YH, Venners SA, Zhang Y, Xing H, Wang X, Xu X. Effects of protein coding polymorphisms in the kallikrein 1 gene on baseline blood pressure and antihypertensive response to irbesartan in Chinese hypertensive patients. J Hum Hypertens. 2011;25(5):327–33.PubMedCrossRef
Metadata
Title
Analysis of the association of ANO3/MUC15, COL4A4, RRBP1, and KLK1 polymorphisms with COPD susceptibility in the Kashi population
Authors
Lifeng Tang
Xuemei Zhong
Hui Gong
Maimaitiaili Tuerxun
Tao Ma
Jie Ren
Chengxin Xie
Aifang Zheng
Zulipikaer Abudureheman
Ayiguzali Abudukadeer
Paierda Aini
Subinuer Yilamujiang
Li Li
Publication date
01-12-2022
Publisher
BioMed Central
Published in
BMC Pulmonary Medicine / Issue 1/2022
Electronic ISSN: 1471-2466
DOI
https://doi.org/10.1186/s12890-022-01975-3

Other articles of this Issue 1/2022

BMC Pulmonary Medicine 1/2022 Go to the issue

Research

Hospital outcomes for patients with pulmonary arterial hypertension in sepsis and septic shock

Research article

Effects of less invasive surfactant administration versus intubation-surfactant-extubation on bronchopulmonary dysplasia in preterm infants with respiratory distress syndrome: a single-center, retrospective study from China

Research

Exploration of induced sputum BIRC3 levels and clinical implications in asthma

Research

Dyspnea and outcome expectations are associated with physical activity in persons with pneumoconiosis: a cross-sectional study

Research

Impact of refractory and unexplained chronic cough on disease burden: a qualitative study

Research

Do hospital workers experience a higher risk of respiratory symptoms and loss of lung function?
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits